Latest Insider Transactions at Bluebird Bio, Inc. (BLUE)
This section provides a real-time view of insider transactions for Bluebird Bio, Inc. (BLUE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of bluebird bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of bluebird bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 06
2024
|
Najoh Tita Reid |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+34.08%
|
-
|
|
Nov 06
2024
|
Elisabeth Leiderman |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+34.56%
|
-
|
|
Nov 06
2024
|
John O Agwunobi |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+32.65%
|
-
|
|
Nov 06
2024
|
Charlotte Jones Burton |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+36.42%
|
-
|
|
Nov 06
2024
|
Richard A. Paulson |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+45.72%
|
-
|
|
Nov 06
2024
|
Nick Leschly |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+7.31%
|
-
|
|
Nov 06
2024
|
Mark Vachon |
BUY
Grant, award, or other acquisition
|
Direct |
24,900
+33.27%
|
-
|
|
Sep 30
2024
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
34,780
-8.48%
|
$0
$0.53 P/Share
|
|
Sep 30
2024
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+24.07%
|
-
|
|
Sep 30
2024
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
1,006
-0.59%
|
$0
$0.53 P/Share
|
|
Sep 30
2024
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.62%
|
-
|
|
Sep 30
2024
|
Michael Cloonan |
BUY
Grant, award, or other acquisition
|
Direct |
37,350
+50.0%
|
-
|
|
Sep 30
2024
|
O. James Sterling Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Sep 30
2024
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+34.53%
|
-
|
|
Sep 30
2024
|
Richard A Colvin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.9%
|
-
|
|
Jun 03
2024
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
3,834
-3.07%
|
$0
$0.97 P/Share
|
|
Mar 04
2024
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
4,573
-3.53%
|
$4,573
$1.53 P/Share
|
|
Mar 04
2024
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
6,095
-2.13%
|
$6,095
$1.53 P/Share
|
|
Mar 01
2024
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,770
-5.41%
|
$6,770
$1.53 P/Share
|
|
Feb 05
2024
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
1,879
-0.65%
|
$0
$0.9 P/Share
|
|
Feb 05
2024
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Open market or private sale
|
Direct |
5,217
-10.43%
|
$0
$0.9 P/Share
|
|
Feb 05
2024
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
2,714
-2.05%
|
$0
$0.9 P/Share
|
|
Jan 05
2024
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
597
-0.47%
|
$597
$1.42 P/Share
|
|
Jan 05
2024
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
3,162
-1.09%
|
$3,162
$1.43 P/Share
|
|
Dec 06
2023
|
Christopher Krawtschuk Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,526
-9.05%
|
$18,104
$4.52 P/Share
|
|
Nov 03
2023
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
807
-0.28%
|
$2,421
$3.17 P/Share
|
|
Nov 02
2023
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,343
-1.83%
|
$4,686
$2.98 P/Share
|
|
Sep 05
2023
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
922
-0.69%
|
$2,766
$3.79 P/Share
|
|
Aug 10
2023
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
16,929
-5.48%
|
$50,787
$3.54 P/Share
|
|
Jun 16
2023
|
Charlotte Jones Burton |
BUY
Grant, award, or other acquisition
|
Direct |
10,790
+36.76%
|
-
|
|
Jun 16
2023
|
Elisabeth Leiderman |
BUY
Grant, award, or other acquisition
|
Direct |
10,790
+32.65%
|
-
|
|
Jun 16
2023
|
Nick Leschly |
BUY
Grant, award, or other acquisition
|
Direct |
10,790
+3.58%
|
-
|
|
Jun 16
2023
|
Mark Vachon |
BUY
Grant, award, or other acquisition
|
Direct |
10,790
+30.11%
|
-
|
|
Jun 16
2023
|
John O Agwunobi |
BUY
Grant, award, or other acquisition
|
Direct |
10,790
+28.96%
|
-
|
|
Jun 16
2023
|
Najoh Tita Reid |
BUY
Grant, award, or other acquisition
|
Direct |
10,790
+31.69%
|
-
|
|
Jun 02
2023
|
Thomas J Klima |
SELL
Open market or private sale
|
Direct |
4,130
-3.01%
|
$12,390
$3.5 P/Share
|
|
Apr 03
2023
|
Richard A. Paulson |
BUY
Grant, award, or other acquisition
|
Direct |
4,663
+50.0%
|
-
|
|
Mar 01
2023
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+28.62%
|
-
|
|
Mar 01
2023
|
Andrew Obenshain President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
67,600
+17.96%
|
-
|
|
Mar 01
2023
|
Richard A Colvin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+30.04%
|
-
|
|
Feb 01
2023
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Feb 01
2023
|
Andrew Obenshain President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,420
-0.59%
|
$8,520
$6.38 P/Share
|
|
Feb 01
2023
|
Richard A Colvin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,153
-1.55%
|
$6,918
$6.38 P/Share
|
|
Feb 01
2023
|
Thomas J Klima |
SELL
Payment of exercise price or tax liability
|
Direct |
2,260
-2.68%
|
$13,560
$6.38 P/Share
|
|
Jan 11
2023
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
4,290
-1.51%
|
$30,030
$7.8 P/Share
|
|
Jan 11
2023
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
557
-0.74%
|
$3,899
$7.8 P/Share
|
|
Jan 11
2023
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
3,178
-1.29%
|
$22,246
$7.8 P/Share
|
|
Dec 01
2022
|
Christopher Krawtschuk Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Nov 04
2022
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
1,263
-0.51%
|
$7,578
$6.41 P/Share
|
|
Nov 04
2022
|
Richard A Colvin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
218
-0.29%
|
$1,308
$6.41 P/Share
|